Current Hypertension Reports

, Volume 9, Issue 4, pp 278–283

The effect of angiotensin receptor blockers for preventing atrial fibrillation

  • Kristian Wachtell
  • Richard B. Devereux
  • Paulette A. Lyle
Article

Abstract

Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice, and causes significant burden to patients and health care systems. Clinicians treat existing atrial fibrillation with anticoagulation and/or drugs that utilize either a rate or rhythm control strategy. It remains unclear how best to reduce cardiovascular morbidity and mortality in this population. Prevention of atrial fibrillation using angiotensin receptor blockers, which affect ion currents and refractoriness in atrial myocytes, regress or prevent atrial fibrosis, decrease left atrial size, regress left ventricular hypertrophy, modulate sympathetic nerve activity, reduce inflammation, and reduce blood pressure, may become an important and desirable alternative.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Wu EQ, Birnbaum HG, Mareva M, et al.: Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005, 21:1693–1699.PubMedCrossRefGoogle Scholar
  2. 2.
    Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69–171PubMedCrossRefGoogle Scholar
  3. 3.
    Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2N–9N.PubMedCrossRefGoogle Scholar
  4. 4.
    Benjamin EJ, Levy D, Vaziri SM, et al.: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271:840–844.PubMedCrossRefGoogle Scholar
  5. 5.
    Camm AJ, Obel OA: Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol 1996, 78:3–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Okcun B, Yigit Z, Kucukoglu MS, et al.: Predictors for maintenance of sinus rhythm after cardioversion in patients with nonvalvular atrial fibrillation. Echocardiography 2002, 19:351–357.PubMedCrossRefGoogle Scholar
  7. 7.
    Gensini F, Padeletti L, Fatini G, et al.: Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003, 26:295–298.PubMedCrossRefGoogle Scholar
  8. 8.
    Tsai CT, Lai LP, Lin JL, et al.: Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004, 109:1640–1646.PubMedCrossRefGoogle Scholar
  9. 9.
    Madrid AH, Peng J, Zamora J, et al.: The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004, 27:1405–1410.PubMedCrossRefGoogle Scholar
  10. 10.
    Healey JS, Baranchuk A, Crystal E, et al.: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005, 45:1832–1839.PubMedCrossRefGoogle Scholar
  11. 11.
    Anand K, Mooss AN, Hee TT, Mohiuddin SM: Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006, 152:217–222.PubMedCrossRefGoogle Scholar
  12. 12.
    Maggioni AP, Latini R, Carson PE, et al.: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005, 149:548–557.PubMedCrossRefGoogle Scholar
  13. 13.
    Wachtell K, Lehto M, Gerdts E, et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:712–719.PubMedCrossRefGoogle Scholar
  14. 14.
    Ducharme A, Swedberg K, Pfeffer MA, et al.: Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006, 152:86–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Schmieder R, Kjeldsen SE, Julius S, et al.: Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial [abstract]. J Hypertens 2006, 24:S3.CrossRefGoogle Scholar
  16. 16.
    Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol 2006, 48:e149–e246.CrossRefGoogle Scholar
  17. 17.
    Verma A, Natale A: Should atrial fibrillation ablation be considered first-line therapy for some patients? Why atrial fibrillation ablation should be considered first-line therapy for some patients. Circulation 2005, 112:1214–1222.PubMedCrossRefGoogle Scholar
  18. 18.
    Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781–788.PubMedCrossRefGoogle Scholar
  19. 19.
    Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992, 327:227–233.CrossRefGoogle Scholar
  20. 20.
    Waldo AL, Camm AJ, deRuyter H, et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol. Lancet 1996, 348:7–12.PubMedCrossRefGoogle Scholar
  21. 21.
    AFFIRM First Antiarrhythmic Drug Substudy Investigators: Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003, 42:20–29.CrossRefGoogle Scholar
  22. 22.
    Madrid AH, Bueno MG, Rebollo JM, et al.: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002, 106:331–336.PubMedCrossRefGoogle Scholar
  23. 23.
    Fogari R, Mugellini A, Destro M, et al.: Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006, 47:46–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Madrid AH, Marin IM, Cervantes CE, et al.: Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004, 5:114–120.PubMedCrossRefGoogle Scholar
  25. 25.
    Wachtell K, Hornestam B, Lehto M, et al.: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:705–711.PubMedCrossRefGoogle Scholar
  26. 26.
    Teo K, Yusuf S, Sleight P, et al.: Rationale, design and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Rampril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004, 148:52–61.PubMedCrossRefGoogle Scholar
  27. 27.
    Goette A, Arndt M, Rocken C, et al.: Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000, 101:2678–2681.PubMedGoogle Scholar
  28. 28.
    Goette A, Staack T, Rocken C, et al.: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000, 35:1669–1677.PubMedCrossRefGoogle Scholar
  29. 29.
    Boldt A, Wetzel U, Weigl J, et al.: Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003, 42:1785–1792.PubMedCrossRefGoogle Scholar
  30. 30.
    Boos CJ, Anderson RA, Lip GY: Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006, 27:136–149.PubMedCrossRefGoogle Scholar
  31. 31.
    Li D, Shinagawa K, Pang L, et al.: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001, 104:2608–2614.PubMedGoogle Scholar
  32. 32.
    Shi Y, Li D, Tardif JC, Nattel S: Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002, 54:456–461.PubMedCrossRefGoogle Scholar
  33. 33.
    Nakashima H, Kumagai K, Urata H, et al.: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000, 101:2612–2617.PubMedGoogle Scholar
  34. 34.
    Kumagai K, Nakashima H, Urata H, et al.: Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003, 41:2197–2204.PubMedCrossRefGoogle Scholar
  35. 35.
    Zhang C, Yasuno S, Kuwahara K, et al.: Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypentrophy. Circ J 2006, 70:335–341.PubMedCrossRefGoogle Scholar
  36. 36.
    Klein HU, Goette A: Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? J Am Coll Cardiol 2003, 41:2205–2206.PubMedCrossRefGoogle Scholar
  37. 37.
    Schiffrin EL: Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002, 113:409–418.PubMedCrossRefGoogle Scholar
  38. 38.
    Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Principal results of the conduit artery function evaluation (CAFE) study. Circulation 2006, 113:1213–1225.PubMedCrossRefGoogle Scholar
  39. 39.
    Olsen MH, Wachtell K, Tuxen C, et al.: Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005, 23:1083–1090.PubMedCrossRefGoogle Scholar
  40. 40.
    Gerdts E, Wachtell K, Omvik P, et al.: Left atrial size and risk of major cardiovascular events during antihypertensive treatment. Losartan Intervention for Endpoint Reduction in Hypertension Trial. Hypertension 2007, 49:311–316.PubMedCrossRefGoogle Scholar
  41. 41.
    Wachtell K, Gerdts E, Aurigemma G, et al.: Does reduction in left atrial diameter during antihypertensive treatment reduce new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the LIFE study [abstract]. J Am Coll Cardiol 2006, 47:9A.Google Scholar
  42. 42.
    Okin PM, Wachtell K, Devereux RB, et al.: Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006, 296:1242–1248.PubMedCrossRefGoogle Scholar
  43. 43.
    Lindholm LH, Dahlöf B, Edelman JM, et al.: Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003, 362:619–620.PubMedCrossRefGoogle Scholar
  44. 44.
    Leistad E, Aksnes G, Verburg E, Christensen G: Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation 1996, 93:1747–1754.PubMedGoogle Scholar
  45. 45.
    Ausma J, Dispersyn GD, Duimel H, et al.: Changes in ultrastructural calcium distribution in goat atria during atrial fibrillation. J Moll Cell Cardiol 2000, 32:355–364.CrossRefGoogle Scholar
  46. 46.
    Shetty SS, DelGrande D: Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan. J Pharmacol Exp Ther 2000, 294:179–186.PubMedGoogle Scholar
  47. 47.
    Cifkova R, Erdine S, Fagard R, et al.: Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003, 21:1779–1786.PubMedCrossRefGoogle Scholar
  48. 48.
    Salehian O, Healey J, Almerri, et al.: Neither ramipril nor vitamin E reduce the incidence of atrial fibrillation. Results of the HOPE study [abstract]. J Am Coll Cardiol 2006, 47(Suppl A):8A–9A.Google Scholar
  49. 49.
    Devereux RB, Wachtell K, Lyle PA: Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation. Curr Cardiol Rep 2006, 8:356–364.PubMedCrossRefGoogle Scholar
  50. 50.
    Arima H, Hart RG, Colman S, et al.: Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2005, 36:2164–2169.PubMedCrossRefGoogle Scholar
  51. 51.
    Celik T, Iyisoy A, Kursaklioglu H, et al.: The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomised clinical study. Clin Cardiol 2005, 28:298–302.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Kristian Wachtell
    • 1
  • Richard B. Devereux
  • Paulette A. Lyle
  1. 1.Department of Cardiology B2142Rigshospitalet, The Heart CenterCopenhagenDenmark

Personalised recommendations